Document:

EX-4.4

 Exhibit 4.4 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE
SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 

AVALANCHE BIOTECHNOLOGIES, INC. 

WARRANT TO PURCHASE SERIES A PREFERRED STOCK 
  

			
	No. PSW-    	  	 [DATE]

 Void After
                         

THIS CERTIFIES THAT, for value received,
                    , an individual residing at
                    , or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined
below) from AVALANCHE BIOTECHNOLOGIES, INC., a Delaware corporation, with its principal office at 2749 Carolina Avenue, Redwood City, CA 94061 (the
“Company”) up to
[                    (            )] shares of the Series A Stock of
the Company (the “Preferred Stock”). 
 Immediately prior to the closing of the Company’s initial public
offering, this warrant shall become exercisable for that number of shares of Common Stock of the Company into which the shares of Preferred Stock issuable under this warrant would then be convertible, so long as such shares, if this warrant has been
exercised prior to such offering, would have been converted into shares of the Company’s Common Stock pursuant to the automatic conversion provisions (or otherwise) of the Company’s Certificate of Incorporation. 

This Warrant is being issued pursuant to the terms of the Note and Warrant Purchase Agreement, dated October
    , 2006 by and among the Company and the Purchasers therewith (the “Note and Warrant Purchase Agreement”). Unless indicated otherwise, the number of shares of Preferred Stock that Holder may purchase by
exercising this warrant is as follows: 
 The number of shares equal to (A) 5% of the Loan Amount, as defined in that
certain Note and Warrant Purchase Agreement, dated as of the date hereof, multiplied by the number of completed calendar months as calculated from the date of this Warrant until the date of the Financing, or up to 50% of the Loan Amount, whichever
is less, multiplied by (C) the per share price of the Series A Preferred Stock sold in the Financing. 
 1.
DEFINITIONS. As used herein, the following terms shall have the following respective meanings: 
 (a)
“Exercise Period” shall mean the period commencing with the date hereof and ending two (2) years later, unless sooner terminated as provided below. 

(b) “Exercise Price” shall mean the share price of the Preferred Stock sold in the Financing, subject to
adjustment pursuant to Section 5 below. 

  
 1. 

 (c) “Exercise Shares” shall mean the shares of the Company’s
Preferred Stock issuable upon exercise of this Warrant, subject to adjustment pursuant to the terms herein, including but not limited to adjustment pursuant to Section 5 below. 

(d) “Financing” shall mean the issuance of the Company’s Series A Preferred Stock for aggregate
consideration (including conversion of any outstanding indebtedness) of at least $900,000. 
 2. EXERCISE
OF WARRANT. The rights represented by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by delivery of the following to the Company at its address set forth above (or at such
other address as it may designate by notice in writing to the Holder): 
 (a) An executed Notice of Exercise in the form attached
hereto; 
 (b) Payment of the Exercise Price either (i) in cash or by check, or (ii) by cancellation of indebtedness; and

 (c) This Warrant. 

Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so purchased, registered in
the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so exercised. 

The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to
have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates, except that, if the date of such
surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on which the stock transfer books are
open. 
 2.1 Net Exercise. Notwithstanding any provisions herein to the contrary, if the fair market value of one share of the
Company’s Preferred Stock is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder may elect to receive shares equal to the value (as determined below)
of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Company together with the properly endorsed Notice of Exercise in which event the Company shall issue to the Holder a number of
shares of Preferred Stock computed using the following formula: 
  
  

 
  

			
	Where X =	  	the number of shares of Preferred Stock to be issued to the Holder

  
 2. 

			
	Y =	  	the number of shares of Preferred Stock purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being canceled (at the date of such calculation)
		
	A =	  	the fair market value of one share of the Company’s Preferred Stock (at the date of such calculation)
		
	B =	  	Exercise Price (as adjusted to the date of such calculation)

 For purposes of the above calculation, the fair market value of one share of Preferred Stock shall be
determined by the Company’s Board of Directors in good faith; provided, however, that in the event that this Warrant is exercised pursuant to this Section 2.1 in connection with the Company’s initial public offering of its Common
Stock, the fair market value per share shall be the product of (i) the per share offering price to the public of the Company’s initial public offering, and (ii) the number of shares of Common Stock into which each share of Preferred
Stock is convertible at the time of such exercise. 
 3. COVENANTS OF THE
COMPANY. 
 3.1 Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise Shares that
may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The
Company further covenants and agrees that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number of shares of its Preferred Stock to provide for the exercise of the
rights represented by this Warrant. If at any time during the Exercise Period the number of authorized but unissued shares of Preferred Stock shall not be sufficient to permit exercise of this Warrant, the Company will take such corporate action as
may, in the opinion of its counsel, be necessary to increase its authorized but unissued shares of Preferred Stock to such number of shares as shall be sufficient for such purposes. 

3.2 Notices of Record Date. In the event of any taking by the Company of a record of the holders of any class of securities for the
purpose of determining the holders thereof who are entitled to receive any dividend (other than a cash dividend which is the same as cash dividends paid in previous quarters) or other distribution, the Company shall mail to the Holder, at least ten
(10) days prior to the date specified herein, a notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution. 

4. REPRESENTATIONS OF HOLDER. 

4.1 Acquisition of Warrant for Personal Account. The Holder represents and warrants that it is acquiring the Warrant and the Exercise
Shares solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any part thereof. The Holder also represents that the entire legal and beneficial interests of the Warrant and
Exercise Shares the Holder is acquiring is being acquired for, and will be held for, its account only. 

  
 3. 

 4.2 Securities Are Not Registered. 

(a) The Holder understands that the Warrant and the Exercise Shares have not been registered under the Securities Act of 1933, as
amended (the “Act”) on the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its
representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the
securities. The Holder has no such present intention. 
 (b) The Holder recognizes that the Warrant and the Exercise Shares must be
held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register the Warrant or the Exercise Shares of the Company, or
to comply with any exemption from such registration. 
 (c) The Holder is aware that neither the Warrant nor the Exercise Shares may
be sold pursuant to Rule 144 adopted under the Act unless certain conditions are met, including, among other things, the existence of a public market for the shares, the availability of certain current public information about the Company, the
resale following the required holding period under Rule 144 and the number of shares being sold during any three month period not exceeding specified limitations. Holder is aware that the conditions for resale set forth in Rule 144 have not been
satisfied and that the Company presently has no plans to satisfy these conditions in the foreseeable future. 
 4.3 Disposition of
Warrant and Exercise Shares. 
 (a) The Holder further agrees not to make any disposition of all or any part of the Warrant or
Exercise Shares in any event unless and until: 
 (i) The Company shall have received a letter secured by the Holder from the
Securities and Exchange Commission stating that no action will be recommended to the Commission with respect to the proposed disposition; 

(ii) There is then in effect a registration statement under the Act covering such proposed disposition and such disposition is made in
accordance with said registration statement; or 
 (iii) The Holder shall have notified the Company of the proposed disposition and
shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished the Company with an opinion of counsel, reasonably
satisfactory to the Company, for the Holder to the effect that such disposition will not require registration of such Warrant or Exercise Shares under the Act or any applicable state securities laws. 

  
 4. 

 (b) The Holder understands and agrees that all certificates evidencing the shares to be
issued to the Holder may bear the following legend: 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED. 
 5. ADJUSTMENT OF EXERCISE PRICE. In
the event of changes in the outstanding Preferred Stock of the Company by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the
number and class of shares available under the Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind
of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment; provided, however, that such adjustment shall not be made with
respect to, and this Warrant shall terminate if not exercised prior to, the events set forth in Section 7 below. The form of this Warrant need not be changed because of any adjustment in the number of Exercise Shares subject to this Warrant.

 6. FRACTIONAL SHARES. No fractional shares shall be issued upon the exercise of this Warrant as a
consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of any fractional share.
If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting
from multiplying the then current fair market value of an Exercise Share by such fraction. 
 7. EARLY
TERMINATION. In the event of, at any time during the Exercise Period, an initial public offering of securities of the Company registered under the Act, or any capital reorganization, or any reclassification of the capital stock of
the Company (other than a change in par value or from par value to no par value or no par value to par value or as a result of a stock dividend or subdivision, split-up or combination of shares), or the consolidation or merger of the Company with or
into another corporation (other than a merger solely to effect a reincorporation of the Company into another state), or the sale or other disposition of all or substantially all the properties and assets of the Company in its entirety to any other
person, the Company shall provide to the Holder twenty (20) days advance written notice of such public offering, reorganization, reclassification, consolidation, merger or sale or other disposition of the Company’s assets, and this Warrant
shall terminate unless exercised prior to the date such public offering is closed or the occurrence of such reorganization, reclassification, consolidation, merger or sale or other disposition of the Company’s assets. 

8. MARKET STAND-OFF AGREEMENT. Holder shall not sell, dispose of, transfer,
make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common Stock (or other securities) of the Company held by Holder, for a period of time
specified by the managing underwriter(s) (not 

  
 5. 

 
to exceed one hundred eighty (180) days) following the effective date of a registration statement of the Company filed under the Act. Holder agrees to execute and deliver such other
agreements as may be reasonably requested by the Company and/or the managing underwriter(s) which are consistent with the foregoing or which are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may
impose stop-transfer instructions with respect to such Common Stock (or other securities) until the end of such period. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 8 and shall have the
right, power and authority to enforce the provisions hereof as though they were a party hereto. 
 9. NO
STOCKHOLDER RIGHTS. This Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a stockholder of the Company. 

10. TRANSFER OF WARRANT. Subject to applicable laws and the restriction on transfer set
forth on the first page of this Warrant, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant and the form of assignment attached hereto to any transferee
designated by Holder. The transferee shall sign an investment letter in form and substance satisfactory to the Company. 
 11.
LOST, STOLEN, MUTILATED OR DESTROYED WARRANT. If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or
otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant
shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 

12. NOTICES, ETC. All notices required or permitted hereunder shall be in writing and shall be deemed
effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed telex or facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (c) five
(5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written
verification of receipt. All communications shall be sent to the Company at the address listed on the signature page and to Holder at
                     or at such other address as the Company or Holder may designate by ten (10) days advance written notice to the other
parties hereto. 
 13. ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement
to all of the terms and conditions contained herein. 
 14. GOVERNING LAW. This Warrant and all rights,
obligations and liabilities hereunder shall be governed by the laws of the State of California. 

  
 6. 

 IN WITNESS WHEREOF, the
Company has caused this Warrant to be executed by its duly authorized officer as of the first date written above. 
  

			
	AVALANCHE BIOTECHNOLOGIES, INC.
		
	By:	 	  

		
	Name:	 	Thomas W. Chalberg, Jr.
		
	Title:	 	CEO and President
		
	Address:	 	2749 Carolina Avenue
		 	Redwood City, CA 94061

  
 7. 

 NOTICE OF EXERCISE 

TO: AVALANCHE BIOTECHNOLOGIES, INC. 

(1)  ̈ The undersigned hereby elects to purchase
                 shares of the Series A Preferred Stock of AVALANCHE BIOTECHNOLOGIES, INC. (the
“Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. 

 ̈ The undersigned hereby elects to purchase
                 shares of the Series A Preferred Stock of AVALANCHE BIOTECHNOLOGIES, INC. (the
“Company”) pursuant to the terms of the net exercise provisions set forth in Section 2.1 of the attached Warrant, and shall tender payment of all applicable transfer taxes, if any. 

(2) Please issue a certificate or certificates representing said shares of Series A Preferred Stock in the name of the undersigned or
in such other name as is specified below: 
  

 
 (Name) 

 
  

 
  

(Address) 
 (3) The
undersigned represents that (i) the aforesaid shares of Series A Preferred Stock are being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that
the undersigned has no present intention of distributing or reselling such shares; (ii) the undersigned is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach
an informed and knowledgeable decision regarding its investment in the Company; (iii) the undersigned is experienced in making investments of this type and has such knowledge and background in financial and business matters that the undersigned
is capable of evaluating the merits and risks of this investment and protecting the undersigned’s own interests; (iv) the undersigned understands that the shares of Series A Preferred Stock issuable upon exercise of this Warrant have not
been registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the registration provisions of the Securities Act, which exemption depends upon, among other things,
the bona fide nature of the investment intent as expressed herein, and, because such securities have not been registered under the Securities Act, they must be held indefinitely unless subsequently registered under the Securities Act or an exemption
from such registration is available; (v) the undersigned is aware that the aforesaid shares of Series A Preferred Stock may not be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met and until the
undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions for use of the Rule is the availability of current information to the public about the Company and the Company has not made such information
available and has no present plans to do so; and (vi) the undersigned agrees not to make any disposition of all or any part of the aforesaid shares of Series A Preferred Stock unless and until there is then in effect a registration statement
under the Securities Act covering such proposed disposition and such disposition is made in accordance with said registration statement, or the undersigned has provided the Company with an opinion of counsel satisfactory to the Company, stating that
such registration is not required. 

					
	  
	 		 	  

	(Date)	 		 	(Signature)
			
		 		 	  

		 		 	(Print name)

 ASSIGNMENT FORM 

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.) 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby
are hereby assigned to 
  

											
	Name:	 	  

											
		 	(Please Print)
		
	Address:	 	  

											
		 	(Please Print)
	
	Dated:                    ,20    
				
	Holder’s	 		  		  	
	Signature:	 	  
	  		  	
						
	Holder’s	 		 		 		  		  	
	Address:	 	  
	  		  	

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant,
without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.EX-10.1

 Exhibit 10.1 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

							
	 1.
	 	BACKGROUND	  	 	1	  
			
	 2.
	 	DEFINITIONS	  	 	2	  
			
	 3.
	 	GRANT	  	 	5	  
			
	 4.
	 	SUBLICENSES	  	 	6	  
			
	 5.
	 	LICENSE ISSUE FEE	  	 	8	  
			
	 6.
	 	ROYALTIES	  	 	9	  
			
	 7.
	 	DUE DILIGENCE	  	 	11	  
			
	 8.
	 	PROGRESS AND ROYALTY REPORTS	  	 	12	  
			
	 9.
	 	BOOKS AND RECORDS	  	 	14	  
			
	 10.
	 	LIFE OF THE AGREEMENT	  	 	14	  
			
	 11.
	 	TERMINATION BY REGENTS	  	 	15	  
			
	 12.
	 	TERMINATION BY LICENSEE	  	 	15	  
			
	 13.
	 	DISPOSITION OF PRODUCTS ON HAND UPON TERMINATION	  	 	16	  
			
	 14.
	 	PATENT PROSECUTION AND MAINTENANCE	  	 	16	  
			
	 15.
	 	MARKING	  	 	17	  
			
	 16.
	 	USE OF NAMES AND TRADEMARKS	  	 	17	  
			
	 17.
	 	LIMITED WARRANTIES	  	 	17	  
			
	 18.
	 	PATENT INFRINGEMENT	  	 	19	  
			
	 19.
	 	INDEMNIFICATION	  	 	20	  
			
	 20.
	 	COMPLIANCE WITH LAWS	  	 	22	  
			
	 21.
	 	GOVERNMENT APPROVAL OR REGISTRATION	  	 	22	  
			
	 22.
	 	ASSIGNMENT	  	 	22	  
			
	 23.
	 	NOTICES	  	 	23	  
			
	 24.
	 	LATE PAYMENTS	  	 	23	  
			
	 25.
	 	WAIVER	  	 	23	  
			
	 26.
	 	CONFIDENTIALITY	  	 	24	  
			
	 27.
	 	FORCE MAJEURE	  	 	25	  
			
	 28.
	 	SEVERABILITY	  	 	25	  
			
	 29.
	 	APPLICABLE LAW; VENUE; ATTORNEYS’ FEES	  	 	25	  
			
	 30.
	 	SCOPE OF AGREEMENT	  	 	26	  

			
	 UNIVERSITY OF CALIFORNIA, BERKELEY
  

OFFICE OF TECHNOLOGY LICENSING
	 	

  
  

 
 EXCLUSIVE LICENSE 

BETWEEN 
 AVALANCHE
BIOTECHNOLOGIES, INC. 
 AND 

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 

FOR 
 USE OF RECOMBINANT
GENE DELIVERY VECTORS FOR TREATING 
 OR PREVENTING DISEASES OF THE EYE 

UC Case No.: [***] 

[***] 
  

 
  

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

			
	 UNIVERSITY OF CALIFORNIA, BERKELEY
  

OFFICE OF TECHNOLOGY LICENSING
	 	

 EXCLUSIVE LICENSE AGREEMENT FOR 

USE OF RECOMBINANT GENE DELIVERY VECTORS FOR TREATING OR 

PREVENTING DISEASES OF THE EYE 

UC Case No.: [***] 

[***] 
 This exclusive license
agreement (“Agreement”) is effective May 27, 2010 (“Effective Date”), by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111 Franklin Street, 12th Floor, Oakland,
California 94607-5200, acting through its Office of Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704-1347 (“REGENTS”) and AVALANCHE BIOTECHNOLOGIES, INC., a Delaware
corporation having a principal place of business at [***] (“LICENSEE”). The parties agree as follows: 
  

	1.	BACKGROUND 

  

	 	1.1	An invention, generally described as “Use Of Recombinant Gene Delivery Vectors For Treating Or Preventing Diseases Of The Eye” and disclosed in Regents’ Case No.: [***] (“INVENTION”), was
jointly made in the course of research at the University of California, Berkeley by [***] and [***], employed by the University of California, Berkeley , and at Chiron Corporation, Emeryville, California (“CHIRON”) by [***] and [***],
employed by Chiron Corporation (“Inventors”). 

  

	 	1.2	Regents’ employees [***] and [***], have assigned to Regents their undivided interest in Patent Rights. 

  

	 	1.3	LICENSEE acknowledges that The REGENTS and CHIRON have not entered into any agreement that sets out the rights of each in regards to licensing of the INVENTION. 

 

	 	1.4	LICENSEE acknowledges that the INVENTION is jointly owned and each party is licensing its interest in PATENT RIGHTS independently of the other. 

  
 1 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	1.5	LICENSEE acknowledges and agrees that the rights granted under this Agreement are granted solely under The REGENTS undivided interest in PATENT RIGHTS, whatsoever those rights might be. 

 

	 	1.6	LICENSEE has provided REGENTS with a commercialization plan for the INVENTION and business strategy in order to evaluate its capabilities as a LICENSEE. 

 

	 	1.7	The development of the INVENTION was sponsored in part by various grants by U.S. Government agencies, and as a consequence, REGENTS elected to retain title to the INVENTION subject to the rights of the U.S. Government
under 35 USC 200-212 and implementing regulations, including that REGENTS, in turn, has granted back to the U.S. Government a non-exclusive, non-tranferable irrevocable, paid-up license to practice or have practiced the INVENTION for or on behalf of
the U.S. Government throughout the world. These U.S. Government grants are [***]. 

  

	 	1.8	REGENTS and LICENSEE wish to have the INVENTION perfected and marketed as soon as reasonably practicable so that products resulting therefrom may be available for public use and benefit. 

 

	 	1.9	LICENSEE wishes to acquire a license under REGENTS’ PATENT RIGHTS for the purpose of undertaking development and to make, have made, use, sell, offer for sale , import, and export LICENSED PRODUCTS as defined
below. 

  

	2.	DEFINITIONS 

  

	 	2.1	“PATENT RIGHTS” means rights in U.S. Patent Number [***] and assigned to REGENTS and to Chiron Corporation, and [***]. 

  

	 	2.2	“REGENT’S PATENT RIGHTS” means the REGENTS’ undivided interest in the PATENT RIGHTS. 

  

	 	2.3	“LICENSED PRODUCTS” means all kits, compositions of matter, articles of manufacture, materials, and products, the manufacture, use, SALE, offer for SALE, or import of which: a) requires the performance of the
LICENSED METHOD; or b) but for the license granted pursuant to this Agreement, would infringe, or contribute to or induce the infringement of, a valid claim of any issued, unexpired patent under REGENTS’ PATENT RIGHTS or a claim being
prosecuted in a pending patent application under REGENTS’ PATENT RIGHTS. A claim in an issued patent under REGENTS’ PATENT RIGHTS will be presumed valid unless and until it has been held to be invalid by a final judgment of a court of
competent jurisdiction from which no appeal can be or is taken. 

  
 2 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	2.4	“LICENSED METHOD” means any process or method the use or practice of which, but for the license pursuant to this Agreement, would infringe, or contribute to or induce the infringement of, any issued or pending
claim under REGENTS’ PATENT RIGHTS in that country in which the LICENSED METHOD is used or practiced. 

  

	 	2.5	“LICENSED FIELD OF USE” means all fields of use. 

  

	 	2.6	“NET SALES” means the gross invoice price charged[***] LICENSEE or a sublicensee of LICENSEE for SALES of LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHODS in the LICENSED TERRITORY, the less the sum
of the following actual and customary deductions where applicable: cash, trade or quantity discounts; sales, use, tariff, import/export duties, excise taxes, value-added taxes or other governmental charges when included in gross sales but not any
income taxes of LICENSEE or its sublicensees derived from such sales freight, insurance, packaging costs, and transportation charges; allowances or credits to customers because of rejections or returns, because of retroactive price reductions, or
due to recalls; and .discounts, rebates, or similar payments granted or given to wholesalers or other distributors, buying groups, health care insurance carriers or other institutions or to the goverment, including Medicare/Medicaid and other
government rebates/discounts. 

 For purposes of calculating NET SALES, SALES among LICENSEE and its sublicensees shall be
disregarded, except that a SALE to a sublicensee for end use by the sublicensee will be treated as a SALE [***]. NET SALES shall exclude any disposition of LICENSED PRODUCTS and LICENSED SERVICES in connection with clinical trials thereof and any
disposition of LICENSED PRODUCTS distributed for promotional or charitable purposes, in reasonable quantities. 
  

	 	2.7	“AFFILIATE” of LICENSEE means any entity that, directly or indirectly, Controls LICENSEE, is Controlled by LICENSEE, or is under common Control with LICENSEE. “Control” means (i) having the
actual, present capacity to elect a majority of the directors of such affiliate, or (ii) having the power to direct at least fifty percent (50%) of the voting rights entitled to elect directors. 

  
 3 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	2.8	“LICENSED TERRITORY” means United States of America, its territories and possessions. 

  

	 	2.9	“SALE” means, for LICENSED PRODUCTS and LICENSED SERVICES, the act of selling, leasing or otherwise transferring, providing, or furnishing such product or service, and for LICENSED METHOD the act of performing
such method, for any use or for any consideration. Correspondingly, “SELL” means to make or cause to be made a SALE, and “SOLD” means to have made or caused to be made a SALE. 

 

	 	2.10	“LICENSED SERVICE” means a service provided using LICENSED PRODUCTS or LICENSED METHOD. 

  

	 	2.11	“FIRST QUALIFIED ROUND” means either (a) actual receipt by LICENSEE of cash funding in excess of [***] US dollars ($[***]) in aggregate including by way of equity financing, convertible debt financing,
grants, sponsored research, collaboration funding; or (b) the closing of an acquisition of all or substantially all of LICENSEE’s stock, assets or business. 

 

	 	2.12	“SUBLICENSEE REVENUE” means any cash consideration [***] due to LICENSEE under each sublicense for the grant of rights under the PATENT RIGHTS in the LICENSED TERRITORY, but excluding: (a) any royalty
payments on sales of LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHODS by a sublicensee (which sales shall be included as NET SALES and shall give rise to royalty payments to REGENTS under section 6.1); (b) any amounts paid by a
sublicensee as bona fide reimbursement for research and development costs [***]; (c) bona fide loans or any payments in consideration for a grant of equity of the LICENSEE [***]; (d) amounts paid for supplies of product or other tangible
materials; (e) amounts paid as reimbursement for expenses directly related to the pursuit, maintenance, and/or defense of PATENT RIGHTS; and (f) withholding taxes and any other amounts by a sublicensee from amounts otherwise payable to
LICENSEE under such sublicense agreement other than past due payments. 

  
 4 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	3.	GRANT 

  

	 	3.1	Subject to the limitations set forth in this Agreement, including the license granted to the U.S. Government and the rights reserved in Paragraph 3.4, REGENTS hereby grants and LICENSEE hereby accepts an exclusive (even
as to REGENTS) license under The REGENTS’ undivided interest in the PATENT RIGHTS to develop, make, have made, use, offer for SALE, import, export, and SELL LICENSED PRODUCTS and LICENSED SERVICES, and to practice the LICENSED METHOD, in the
LICENSED FIELD OF USE in the LICENSED TERRITORY. 

  

	 	3.2	LICENSEE acknowledges that CHIRON has the right to grant licenses to its undivided interest in PATENT RIGHTS. 

  

	 	3.3	The license under Paragraph 3.1 will be exclusive for a term commencing on the Effective Date and ending on the date of expiration of PATENT RIGHTS. 

 

	 	3.4	Nothing in this Agreement will be deemed to limit the right of REGENTS to publish any and all technical data resulting from any research performed by REGENTS relating to the INVENTION, and to make and use the INVENTION,
LICENSED PRODUCTS, and LICENSED SERVICES and practice LICENSED METHOD and to allow other educational and non-profit institutions to do so for educational and research purposes, provided that in all cases REGENTS complies with Article 26 with respect
to any information provided by LICENSEE. 

  

	 	3.5	This Agreement will terminate immediately if LICENSEE files a claim that includes, in any way, the assertion that any portion of the PATENT RIGHTS is invalid or unenforceable where the filing is by the LICENSEE, a third
party on behalf of the LICENSEE (and with the actual knowledge of the LICENSEE), or a third party at the written urging of the LICENSEE. 

  

	 	3.6	LICENSEE will have a continuing responsibility to keep REGENTS informed of the large/small entity status, as defined in 15 U.S.C. 632, of itself and its sublicensees. 

 

	 	3.7	The INVENTION was funded in part by the U.S. Government. In accordance with PL 96-517 as amended by PL 98-620, to the extent required by law or regulation, any products covered by patent applications or patents claiming
the INVENTION and sold in the United States will be substantially manufactured in the United States. 

  
 5 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	4.	SUBLICENSES 

  

	 	4.1	REGENTS also grants to LICENSEE the right to sublicense to AFFILIATES and third parties the right to develop, make, have made, use, offer for SALE, import, export, and SELL LICENSED PRODUCTS and LICENSED SERVICES, and
to practice LICENSED METHOD[***]. Every such sublicense will include: 

  

	 	(a)	a statement setting forth the date upon which LICENSEE’s exclusive rights, privileges, and license hereunder will expire; 

  

	 	(b)	as applicable, all the rights of, and require the performance of all the obligations due to, REGENTS (and, if applicable, the United States Government) under this Agreement other than (i) any payment or reporting
obligations (for which LICENSEE is directly responsible pursuant to Paragraph 4.6) and (ii) the indemnification obligation in Article 19 (which are addressed in Paragraph 4.1(d)),; 

 

	 	(c)	a prohibition on the grant of further sublicenses; and 

  

	 	(d)	the same provision for indemnification of REGENTS as has been provided for in this Agreement. 

  

	 	4.2	LICENSEE will pay to REGENTS [***] percent ([***]%) of SUBLICENSE REVENUE. 

 In the event
LICENSEE sublicenses the PATENT RIGHTS along with its own patent rights or those of other third parties, LICENSEE may reasonably determine in good faith the percentage of compensation received thereunder that represents consideration due for the
grant of the rights under the PATENT RIGHTS in the LICENSED TERRITORY, which percentage will be based upon the value of the PATENT RIGHTS licensed to the sublicensee relative to the value of the other third party patent rights licensed to the
sublicensee. When making payment under this Paragraph 4.2, LICENSEE shall provide REGENTS with all supporting information and documentation used to determine any such percentage (or shall reference previously provided supporting information and
documentation) 

  
 6 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	4.3	LICENSEE will notify REGENTS of each sublicense granted hereunder and furnish to REGENTS a copy of each such sublicense agreement. Such copy may be redacted by LICENSEE to protect sensitive information. However, such
copy shall contain sufficient information to assure REGENTS that the sublicense is consistent with this Agreement, and under no circumstances shall any financial terms necessary to calculate payments due to REGENTS hereunder be redacted.

  

	 	4.4	AFFILIATES will have no licenses under REGENTS’ PATENT RIGHTS except as granted by sublicense pursuant to this Agreement. 

  

	 	4.5	For the purposes of this Agreement, the operations of all sublicensees shall be deemed to be the operations of LICENSEE, for which LICENSEE shall be responsible. 

 

	 	4.6	LICENSEE will be responsible for payment of all monies and other consideration due REGENTS hereunder as a result of the activities of sublicensees, and all reports due REGENTS hereunder will reflect such activities.

  

	 	4.7	Upon termination of this Agreement for any reason, all sublicenses that are granted by LICENSEE pursuant to this Agreement where the sublicensee is in compliance with its sublicense agreement as of the date of such
termination will survive such termination (as a direct license(s) from REGENTS), provided that (a) each such direct license shall be subject to the same non-financial terms and conditions as those in this Agreement, except that REGENTS will not
be bound to perform any duties or obligations set forth in any sublicenses that extend beyond the duties and obligations of REGENTS set forth in this Agreement; (b) such sublicensee (or if there is at such time more than one such sublicensee,
such sublicensees severally and jointly) shall be required to make any annual maintenance payments due pursuant to Paragraph 5.2 or any minimum annual royalties due pursuant to Paragraph 6.7; and (c) and such sublicensee shall be required to
make any other monetary payment(s) that, had this Agreement not been terminated, LICENSEE would have been required to make under this Agreement as a result of the license to or activities of such sublicensee. 

  
 7 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	4.8	If REGENTS (to the extent of the actual knowledge of the licensing professional responsible for administration of this case) or a third party discovers and notifies that licensing professional that the INVENTION is
useful for an application covered by the LICENSED FIELD OF USE, but for which LICENSED PRODUCTS have not been developed or are not currently under development by LICENSEE, and provided that such application does not compete, directly with LICENSED
PRODUCTS that have been developed or are currently under development by LICENSEE [ok to disclose; in company’s favor] (such application, the “NEW APPLICATION”), then REGENTS, as represented by the Office of Technology Licensing, shall
give written notice to LICENSEE[***]. 

 LICENSEE shall have [***] to give REGENTS written notice stating whether
LICENSEE elects to develop LICENSED PRODUCTS for the NEW APPLICATION. 
 If LICENSEE elects to develop and commercialize the proposed
LICENSED PRODUCTS for the NEW APPLICATION, LICENSEE shall submit progress reports to REGENTS pursuant to Article 8. 
 If LICENSEE elects
[***] for use in the NEW APPLICATION, REGENTS may [***] for the NEW APPLICATION. If REGENTS [***] under this Agreement, then LICENSEE shall [***] from the date [***], then LICENSEE shall [***] pursuant to Paragraph [***]. LICENSEE shall [***] under
this Paragraph 4.8 (and, for clarity, the subsequent paragraph [***] described above. 
 If LICENSEE [***] with respect to the NEW
APPLICATION, then [***] LICENSEE shall [***] and a [***] for LICENSEE’s [***]. If REGENTS, [***], then REGENTS shall have [***] by LICENSEE. 
  

	5.	LICENSE ISSUE FEE 

  

	 	5.1	LICENSEE will pay to REGENTS a non-creditable, non-refundable license issue fee as follows. This fee is non-refundable and not an advance against royalties or other payments due under this Agreement: 

  
 8 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	(a)	[***] US Dollars ($[***]) due within thirty (30) days of the signing of the Agreement and; 

  

	 	(b)	An additional [***] United States Dollars ($[***]) shall be due within -six (6) months after the FIRST QUALIFIED ROUND or on the second anniversary of the Effective Date of this Agreement, whichever comes first.

  

	 	5.2	LICENSEE will also pay to REGENTS an annual license maintenance fee of [***] U.S. dollars ($[***]) beginning on the first anniversary of the Effective Date and on each anniversary of the Effective Date thereafter for
the term of the AGREEMENT. Notwithstanding the foregoing, the license maintenance fee will not be due and payable on any anniversary of the Effective Date following the first SALE of a LICENSED PRODUCT, LICENSED METHOD OR LICENSED SERVICE in the
LICENSED TERRITORY after USFDA approval. 

  

	6.	ROYALTIES 

  

	 	6.1	LICENSEE will pay to REGENTS earned royalties at the rate of [***] percent ([***]%) of NET SALES, subject to the following: 

  

	 	(a)	If LICENSEE is required to make any payment (including royalties or other license fees) to a third party to obtain a patent license or other patent rights in the absence of which LICENSEE could not practice
REGENTS’ PATENT RIGHTS, such third party payments will be creditable against royalties owed hereunder by LICENSEE to REGENTS, provided that in no one calendar year will the total of such credits reduce earned royalties owed by LICENSEE to
REGENTS by more than [***] on NET SALES of LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHODS. 

  

	 	(b)	In the event a LICENSED PRODUCT, LICENSED SERVICE and LICENSED METHODS is, or LICENSED PRODUCTS, LICENSED SERVICES and LICENSED METHODS are, combined with other licensed technologies for sales to end users by LICENSEE
and the total combined royalty burden to LICENSEE on NET SALES [***], the earned royalty due to REGENTS will be adjusted, according to the following formula, where [***] and [***] on LICENSEE : 

  
 9 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 [***] 

For example, if LICENSEE’s total combined royalty is [***], the adjusted royalty due from LICENSEE to REGENTS would be calculated as
[***]. Notwithstanding the foregoing, in no event will the royalty due to REGENTS under this adjustment be less than [***] percent ([***]%) (i.e., not less than [***] percent ([***]%) of [***]%). 

 

	 	6.2	Royalties accruing to REGENTS will be paid to REGENTS quarterly within [***] after the end of each calendar quarter. 

  

	 	6.3	LICENSEE will pay to REGENTS a milestone payment of [***]. 

  

	 	6.4	LICENSEE will pay to REGENTS a milestone payment of [***]. 

  

	 	6.5	LICENSEE will pay to REGENTS a milestone payment of [***]. 

  

	 	6.6	LICENSEE will pay to REGENTS a milestone payment of [***]. 

  

	 	6.7	Beginning in the calendar year after the first SALE of a LICENSED PRODUCT OR LICENSED SERVICE or LICENSED METHOD in the LICENSED TERRITORY, and in each succeeding calendar year thereafter LICENSEE will pay to REGENTS a
minimum annual royalty of [***] for the life of this Agreement. This minimum annual royalty will be paid to REGENTS [***] and will be [***] for the calendar year in which [***]. 

 

	 	6.8	All payments due REGENTS will be payable in United States dollars. When LICENSED PRODUCTS, LICENSED SERVICES, or LICENSED METHOD are SOLD for monies other than United States dollars, earned royalties will first be
determined in the foreign currency of the country in which the SALE was made and then converted into equivalent United States dollars. The exchange rate will be that rate quoted in the Wall Street Journal on the last business day of the
reporting period. 

  
 10 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	6.10	LICENSEE will make all payments under this Agreement by check payable to “The Regents of the University of California” and forward it to REGENTS at the address shown in Article 23 (Notices). 

 

	 	6.11	If any patent or patent application, or any claim thereof, included within REGENTS’ PATENT RIGHTS expires or is held invalid in a final decision by a court of competent jurisdiction and last resort and from which
no appeal has been or can be taken, all obligation to pay royalties based on such patent, patent application or claim, or any claims patentably indistinct therefrom will cease as of the date of such expiration or final decision. LICENSEE will not,
however, be relieved from paying any royalties that accrued before such expiration or decision or that are based on another valid patent or claim not expired or involved in such decision. 

 

	 	6.12	No earned royalties will be collected or paid hereunder on SALES to, or for use by, the United States Government. LICENSEE will reduce the amount charged for such SALES by an amount equal to the earned royalty otherwise
due REGENTS as provided herein. 

  

	7.	DUE DILIGENCE 

  

	 	7.1	LICENSEE, upon execution of this Agreement, will diligently proceed with the development, manufacture, and SALE of LICENSED PRODUCTS, LICENSED SERVICES, and LICENSED METHOD, and will diligently market them in quantities
sufficient to meet the market demand. 

  

	 	7.2	In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving the following objectives in its due diligence activities under this Agreement: 

[***] 
  

	 	7.3	 If LICENSEE is unable to meet any of its diligence obligations set forth in Paragraphs 7.1 and 7.2, then REGENTS will so notify LICENSEE of failure to
perform. LICENSEE will have the right and option to extend the target date of any such due diligence obligation for a period of six (6) months upon the payment of [***] dollars ($[***]) within [***] of the date to be extended for each such

  
 11 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	
extension option exercised by LICENSEE. LICENSEE may further extend the target date of any diligence obligation for an additional six (6) months upon payment of an additional [***] dollars
($[***]). Additional extensions may be granted only by mutual written agreement of the parties to this Agreement. These payments are in addition to the minimum royalty payments specified in Paragraph 6.4. Should LICENSEE opt not to extend the
obligation or fail to meet it by the extended target date, then REGENTS will have the right and option either terminate this Agreement or to reduce LICENSEE’s exclusive license to a non-exclusive royalty-bearing license, with all payments
hereunder reduced to [***]. This right, if exercised by REGENTS[***]. The right to terminate this Agreement or reduce LICENSEE’s exclusive license granted hereunder to a non-exclusive license will be REGENTS’ sole remedy for breach of
Paragraph 7.1 or 7.2. 

  

	 	7.4	At the request of either party, any controversy or claim arising out of or relating to the diligence provisions of Paragraphs 7.1 and 7.2 will be settled by arbitration conducted in San Francisco, California in
accordance with the then current Commercial Arbitration Rules of the American Arbitration Association. Judgment upon the award rendered by the arbitrator(s) will be binding on the parties and may be entered by either party in the court or forum
having jurisdiction. In determination of due diligence, the arbitrator may determine solely the issues of fact or law with respect to termination of LICENSEE’s rights under this Agreement but will not have the authority to award monetary
damages or grant equitable relief. 

  

	 	7.5	To exercise either the right to terminate this Agreement or to reduce the license to a non-exclusive license for lack of diligence under Paragraph 7.1 or 7.2, REGENTS will give LICENSEE written notice of the deficiency.
LICENSEE thereafter has [***] to cure the deficiency or to request arbitration. If REGENTS has not received a written request for arbitration or satisfactory tangible evidence that the deficiency has been cured by the end of the [***] period, then
REGENTS may, at its option, either terminate the Agreement or reduce LICENSEE’s exclusive license to a non-exclusive license, with all payments hereunder reduced to [***], by giving written notice to LICENSEE. These notices will be subject to
Article 23 (Notices). 

  

	8.	PROGRESS AND ROYALTY REPORTS 

  

	 	8.1	For the period beginning October 30, 2010, LICENSEE will submit to REGENTS a semi annual progress report covering LICENSEE’s activities related to the development and testing of all LICENSED PRODUCTS, LICENSED
SERVICES and LICENSED METHOD and the obtaining of necessary governmental approvals, if any, for marketing in the United States. These progress reports will be made for all development activities until the first SALE occurs in the United States.

  
 12 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	8.2	Each progress report will be a sufficiently detailed summary of activities of LICENSEE and any sublicensees so that REGENTS may evaluate and determine LICENSEE’s progress in development of LICENSED PRODUCTS,
LICENSED SERVICES, and LICENSED METHOD, and in meeting its diligence obligations under Article 7, and will include (but not be limited to) the following: summary of work completed and in progress; current schedule of anticipated events and
milestones, including diligence milestones under Paragraph 7.2; anticipated market introduction dates for the licensed territories; and sublicensee’s activities during the reporting period. 

 

	 	8.3	LICENSEE also will report to REGENTS in its immediately subsequent progress and royalty reports, the date of first SALE. 

  

	 	8.4	After the first SALE giving rise to NET SALES, LICENSEE will make quarterly royalty reports to REGENTS within [***] after the quarters ending March 31, June 30, September 30, and
December 31, of each year. Each such royalty report will include at least the following: 

  

	 	(a)	The number of LICENSED PRODUCTS SOLD in the TERRITORY; 

  

	 	(b)	Gross revenue from SALE of LICENSED PRODUCTS and LICENSED SERVICES and LICENSED METHOD in the TERRITORY; 

  

	 	(c)	NET SALES pursuant to Paragraph 2.5; 

  

	 	(d)	Total royalties due REGENTS; and 

  

	 	(e)	Names and addresses of any new sublicensees along with a summary of the material terms of each new sublicense agreement entered into during the reporting quarter. 

 

	 	8.5	If no SALES have occurred in the TERRITORY during the report period, a statement to this effect is required in the royalty report for that period. 

  
 13 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	9.	BOOKS AND RECORDS 

  

	 	9.1	LICENSEE will keep full, true, and accurate books and records containing all particulars that may be necessary for the purpose of showing the amount of royalties payable to REGENTS and LICENSEE’s compliance with
other obligations under this Agreement. Said books and records will be kept at LICENSEE’s principal place of business or the principal place of business of the appropriate division of LICENSEE to which this Agreement relates. Said books and
records and the supporting data will be open at all reasonable times during normal business hours upon reasonable notice, for [***] years following the end of the calendar year to which they pertain, to the inspection and audit by representatives of
REGENTS for the purpose of verifying LICENSEE’s royalty statement or compliance in other respects with this Agreement. Prior to any such inspection, such representatives will agree in a written agreement with LICENSEE to hold all information in
confidence except as necessary to communicate LICENSEE’s non-compliance with this Agreement to REGENTS. 

  

	 	9.2	The fees and expenses of REGENTS’ representatives performing such an examination will be borne by REGENTS. However, if an error in underpaid royalties to REGENTS of more than [***] percent ([***]%) of the total
royalties due for any year is discovered, then the fees and expenses of these representatives will be borne by LICENSEE. 

  

	10.	LIFE OF THE AGREEMENT 

  

	 	10.1	Unless otherwise terminated by the operation of law or by acts of the parties in accordance with the terms of this Agreement, this Agreement will be in force from the Effective Date and will remain in effect for the
life of the last-to-expire patent. 

  

	 	10.2	Any termination of this Agreement shall not affect the rights and obligations set forth in the following articles: 

  

			
	 Article 2
	  	Definitions
	 Article 4
	  	Sublicenses
	 Article 9
	  	Books and Records
	 Article 10
	  	Life of the Agreement
	 Article 13
	  	Disposition of Licensed Products On Hand Upon Termination

  
 14 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

			
	 Article 16
	  	Use of Names and Trademarks
	 Article 17
	  	Limited Warranties
	 Article 19
	  	Indemnification
	 Article 23
	  	Notices
	 Article 24
	  	Late Payments
	 Article 26
	  	Confidentiality
	 Article 29
	  	Applicable Law; Venue; Attorneys’ Fees

  

	 	10.3	Any termination of this Agreement will not relieve LICENSEE of its obligation to pay any monies due or owing at the time of such termination and will not relieve any obligations, of either party to the other party,
established prior to termination. 

  

	11.	TERMINATION BY REGENTS 

  

	 	11.1	If LICENSEE should violate or fail to perform any term of this Agreement, then REGENTS may give written notice of such default (“Notice of Default”) to LICENSEE. If LICENSEE should fail to repair such default
within sixty (60) days of the effective date of such notice, REGENTS will have the right to terminate this Agreement and the licenses herein by a second written notice (“Notice of Termination”) to LICENSEE. If a Notice of Termination
is sent to LICENSEE, this Agreement will automatically terminate on the effective date of such notice. Such termination will not relieve LICENSEE of its obligation to pay any royalty or license fees owing at the time of such termination and will not
impair any accrued rights of REGENTS. These notices will be subject to Article 23 (Notices). 

  

	12.	TERMINATION BY LICENSEE 

  

	 	12.1	LICENSEE will have the right at any time to terminate this Agreement in whole or as to any portion of REGENTS’ PATENT RIGHTS by giving notice in writing to REGENTS. Such notice of termination will be subject to
Article 23 (Notices) and termination of this Agreement will be effective (30) days after the effective date of such notice. 

  

	 	12.2	Any termination pursuant to Paragraph 12.1 will not relieve LICENSEE of any obligation or liability accrued hereunder prior to such termination or rescind anything done by LICENSEE or any payments made to REGENTS
hereunder prior to the time such termination becomes effective, and such termination will not affect in any manner any rights of REGENTS arising under this Agreement prior to such termination. 

  
 15 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	13.	DISPOSITION OF LICENSED PRODUCTS ON HAND UPON TERMINATION 

  

	 	13.1	Upon termination of this Agreement, [***] LICENSEE may complete and SELL any partially made LICENSED PRODUCTS and continue to render any previously commenced LICENSED SERVICES, and continue the practice of LICENSED
METHOD only to the extent necessary to do so; provided, however, that all such SALES will be subject to the terms of this Agreement including, but not limited to, the payment of royalties at the rate and at the time provided herein and the rendering
of reports thereon. 

  

	14.	PATENT PROSECUTION AND MAINTENANCE 

  

	 	14.1	REGENTS will diligently maintain the United States patent under REGENTS’ PATENT RIGHTS, subject to LICENSEE’S reimbursement of REGENTS’ out of pocket costs under Article 14.3 below. 

 

	 	14.2	Subject to Paragraphs 14.1 and 14.3, all past and future patent costs paid by REGENTS for the prosecution and maintenance of the PATENT RIGHTS will be borne by LICENSEE, so long as the licenses granted to LICENSEE
herein are exclusive. To date the remaining past patent costs paid by REGENTS are about [***] Dollars ($[***] ). Payments are due within [***] days after receipt of invoice from REGENTS, except that no payment shall be required until [***] after the
FIRST QUALIFIED ROUND or on the first anniversary of the Effective Date of this Agreement, whichever comes first. If, however, REGENTS reduces the exclusive licenses granted herein to non-exclusive licenses pursuant to Paragraphs 7.3, 7.4, or 7.5
and REGENTS grants additional license(s), the costs paid by REGENTS for maintaining the PATENT RIGHTS will be [***] from the [***]. 

  

	 	14.3	LICENSEE’s obligation to underwrite and to pay patent costs in accordance with this Article 14 will continue for so long as this Agreement remains in effect. 

  
 16 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	15.	MARKING 

  

	 	15.1	LICENSEE agrees to mark LICENSED PRODUCT(S) (or their containers or labels) made, sold, licensed or otherwise disposed of in the United States under the license granted in this Agreement with the patent number of any
applicable U.S. patent in the LICENSED PATENTS. 

  

	16.	USE OF NAMES AND TRADEMARKS 

  

	 	16.1	Nothing contained in this Agreement will be construed as conferring any right to use in advertising, publicity or other promotional activities any name, trademark, trade name, or other designation of either party hereto
by the other (including any contraction, abbreviation, or simulation of any of the foregoing). Unless required by law or consented to in writing by REGENTS, the use by LICENSEE of the name “The Regents of the University of California” or
the name of any University of California campus in advertising, publicity or other promotional activities is expressly prohibited. Unless required by law or consented to in writing by LICENSEE, the use by REGENTS of the name “Avalanche
Biotechnologies” in advertising, publicity or other promotional activities is expressly prohibited. 

  

	17.	LIMITED WARRANTIES 

  

	 	17.1	REGENTS warrants to LICENSEE that it has the lawful right to grant this license under The REGENTS’ undivided interest in the PATENT RIGHTS. 

 

	 	17.2	To the extent of the actual knowledge of the licensing professional responsible for administration of the Agreement as of the Effective Date, it is a joint owner of the PATENT RIGHTS, and it has not granted any right,
license or interest in or to the REGENT’S PATENT RIGHTS to any third party. 

  

	 	17.3	To the extent of the actual knowledge of the licensing professional responsible for administration of the Agreement as of the Effective Date, except as it may have previously disclosed to Avalanche in writing, there are
no interferences or oppositions pending or, to REGENTS knowledge, threatened against REGENTS before any court or administrative office or agency with respect to the PATENT RIGHTS. 

  
 17 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	17.4	To the extent of the actual knowledge of the licensing professional responsible for administration of the Agreement as of the Effective Date, the Licensed Patents are subsisting and are not invalid or unenforceable, in
whole or in part. 

  

	 	17.5	To the extent of the actual knowledge of the licensing professional responsible for administration of the Agreement as of the Effective Date, the PATENT RIGHTS are not being infringed by any third party.

  

	 	17.6	EXCEPT AS PROVIDED HEREIN, this license and the associated INVENTION are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, AND REGENTS MAKES NO
REPRESENTATION OR WARRANTY THAT THE INVENTION, REGENTS’ PATENT RIGHTS, LICENSED PRODUCTS, LICENSED SERVICES OR LICENSED METHOD WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT. 

 

	 	17.7	IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES UNDER THIS AGREEMENT OR RESULTING FROM EXERCISE OF THIS LICENSE OR THE USE OF THE INVENTION, REGENTS’ PATENT
RIGHTS, LICENSED METHOD, LICENSED SERVICES OR LICENSED PRODUCTS. THE FOREGOING IS NOT INTENDED TO LIMIT LICENSEE’S OBLIGATIONS UNDER ARTICLE 19. 

  

	 	17.8	Except as expressly provided in this Article 17, nothing in this Agreement is or will be construed as: 

  

	 	(a)	A warranty or representation by REGENTS as to the validity, enforceability or scope of any REGENTS’ PATENT RIGHTS; or 

  

	 	(b)	A warranty or representation that anything made, used, or SOLD under any license granted in this Agreement is or will be free from infringement of patents of third parties; or 

 

	 	(c)	An obligation to bring or prosecute actions or suits against third parties for patent infringement, except as provided in Article 18; or 

  
 18 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	(d)	Conferring by implication, estoppel, or otherwise any license or rights under any patents of REGENTS other than REGENTS’ PATENT RIGHTS as defined herein, regardless of whether such patents are dominant or
subordinate to REGENTS’ PATENT RIGHTS; or 

  

	 	(e)	An obligation to furnish any know-how not provided in the patents and patent applications under REGENTS’ PATENT RIGHTS. 

  

	18.	PATENT INFRINGEMENT 

  

	 	18.1	In the event that a party ( in the case of the REGENTS to the extent of the actual knowledge of the licensing professional responsible for the administration of this Agreement) learns of the substantial infringement of
any REGENTS’ PATENT RIGHTS under this Agreement, such party will promptly provide the other party with notice and reasonable evidence of such infringement (“Infringement Notice”). During the period and in a jurisdiction where LICENSEE
has exclusive rights under this Agreement, neither party will notify a third party, including the infringer, of the infringement without first obtaining consent of the other party, which consent will not be unreasonably withheld. Both parties will
use diligent efforts, in cooperation with each other, to terminate such infringement without litigation. 

  

	 	18.2	LICENSEE shall have the first right to institute suit for patent infringement against the infringer [***] after the Infringement Notice in 18.1. REGENTS may voluntarily join such suit at its own expense, but may not
thereafter commence suit against the infringer for the acts of infringement that are the subject of LICENSEE’s suit or any judgment rendered in that suit. LICENSEE may not join REGENTS in a suit initiated by LICENSEE without REGENTS’ prior
written consent. If, in a suit initiated by LICENSEE, REGENTS is involuntarily joined other than by LICENSEE, [***] by REGENTS arising out of such suit, [***] in the suit. 

If, within [***] following the effective date of the Infringement Notice, the infringing activity of potential commercial
significance has not been abated and if LICENSEE has not brought suit against the infringer, REGENTS may institute suit for patent infringement against the infringer. If REGENTS institutes such suit, LICENSEE may not join such suit without
REGENTS’ consent and may not thereafter commence suit against the infringer for the acts of infringement that are the subject of REGENTS’ suit or any judgment rendered in that suit. 

  
 19 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	18.3	Such legal action as is decided upon will be at the expense of the party on account of whom suit is brought and all recoveries recovered thereby will belong to such party, provided that legal action brought jointly by
REGENTS and LICENSEE and participated in by both, will be at the joint expense of the parties and all recoveries will be allocated in the following order: a) to each party reimbursement in equal amounts of the attorney’s costs, fees, and other
related expenses to the extent each party paid for such costs, fees, and expenses until all such costs, fees, and expenses are consumed for each party; and b) any remaining amount shared jointly by them in proportion to the share of expenses paid by
each party[***]. 

  

	 	18.4	Each party will cooperate with the other in litigation instituted hereunder but at the expense of the party on account of whom suit is brought. Such litigation will be controlled by the party bringing the action, except
that REGENTS may be represented by counsel of its choice in any suit brought by LICENSE. 

  

	 	18.5	Any agreement made by LICENSEE for the purposes of settling litigation or other dispute shall comply with the requirements of Article 4 (Sublicenses) of this Agreement. 

 

	19.	INDEMNIFICATION 

  

	 	19.1	LICENSEE will, and will require its sublicensees to, indemnify, hold harmless, and defend REGENTS and its officers, employees, and agents sponsor(s) of the research that led to the INVENTION; and the inventors of the
patent under REGENTS’ PATENT RIGHTS and their employers against any and all third party claims or suits, and any losses, damages, costs, fees, and expenses arising therefrom, to the extent resulting from or arising out of [***]. This
indemnification will include, but not be limited to, any product liability. The foregoing indemnity shall not apply to the extent the applicable claim, suit, losses, damages, costs, fees, or expenses result from or arise out of REGENT’s breach
of this Agreement. 

  

	 	19.2	LICENSEE or its collaborators and/or AFFILIATES, at their sole cost and expense, will insure its activities in connection with any work performed under the LICENSED PRODUCTS in the LICENSED TERRITORY and will obtain,
keep in force, and maintain the following insurance: 

  
 20 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	(a)	Commercial Form General Liability Insurance (contractual liability included) with limits as follows: 

  

					
	 Each Occurrence
	  	$	[	***] 
	 Products/Completed Operations Aggregate
	  	$	[	***] 
	 Personal and Advertising Injury
	  	$	[	***] 
	 General Aggregate
	  	$	[	***] 

 If the above insurance is written on a claims-made form, it shall provide for a [***] tail covering claims
arising from activities prior to termination or expiration of this Agreement. The insurance shall have a retroactive date of placement prior to or coinciding with the Effective Date of this Agreement; and 

 

	 	(b)	Worker’s Compensation as legally required in the jurisdiction in which LICENSEE is doing business. 

  

	 	19.3	The coverage and limits referred to in Subparagraphs 19.2a and 19.2b above will not in any way limit the liability of LICENSEE under this Article. Within ninety (90) days of the execution of this Agreement,
LICENSEE will furnish REGENTS with certificates of insurance evidencing compliance with all requirements. Such certificates will: 

  

	 	(a)	indicate that REGENTS has been endorsed as an additional insured under the coverage described above in Subparagraph l9.2; and 

  

	 	(b)	include a provision that the coverage will be primary and will not participate with, nor will be excess over, any valid and collectable insurance or program of self-insurance maintained by REGENTS. 

 

	 	19.4	REGENTS will promptly notify LICENSEE in writing of any claim or suit brought against REGENTS for which REGENTS intends to invoke the provisions of this Article 19. LICENSEE will keep REGENTS informed of its defense of
any claims pursuant to this Article 19, and REGENTS will reasonably cooperate in any such defense. It is understood that some of the REGENTS employees are academic employees. So long as LICENSEE is actively defending a claim or suit pursuant to this
Article 19 in good faith, REGENTS shall not settle any such claim or suit without the prior written consent of LICENSEE. LICENSEE may not admit liability or wrong doing on the part of an Indemnitee without the REGENTS written consent.

  
 21 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	20.	COMPLIANCE WITH LAWS 

  

	 	20.1	LICENSEE will comply with all applicable international national, state, regional, and local laws and regulations in performing its obligations hereunder and in its use, manufacture, SALE or import of the LICENSED
PRODUCTS, LICENSED SERVICES, or practice of the LICENSED METHOD. LICENSEE understands that REGENTS is subject to United States laws and regulations (including the Arms Export Control Act, as amended, and the Export Administration Act of 1979),
controlling the export of technical data, computer software, laboratory prototypes and other commodities, and REGENTS’ obligations under this Agreement are contingent on compliance with such laws and regulations. The transfer of certain
technical data and commodities may require a license from the cognizant agency of the United States Government and/or written assurances by LICENSEE that LICENSEE will not export such technical data and/or commodities to certain foreign countries
without prior approval of such agency. REGENTS neither represents that a license will not be required nor that, if required, it will be issued. 

  

	21.	GOVERNMENT APPROVAL OR REGISTRATION 

  

	 	21.1	If this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency, LICENSEE will assume all legal obligations to do so. LICENSEE will
notify REGENTS if it becomes aware that this Agreement is subject to a United States or foreign government reporting or approval requirement. LICENSEE will make all necessary filings and pay all costs including fees, penalties, and all other
out-of-pocket costs associated with such reporting or approval process. 

  

	22.	ASSIGNMENT 

  

	 	22.1	This Agreement is binding upon and shall inure to the benefit of REGENTS, its successors and assigns. This Agreement will be personal to LICENSEE and assignable by LICENSEE only with the written consent of REGENTS,
except that LICENSEE may freely assign this Agreement to an acquirer of all or substantially all of LICENSEE’s stock, assets or business. 

  
 22 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	23.	NOTICES 

  

	 	23.1	All notices under this Agreement will be deemed to have been fully given and effective when done in writing and delivered in person, or mailed by registered or certified U.S. mail, or deposited with a carrier service
requiring signature by recipient, and addressed as follows: 

  

			
	To REGENTS:	  	Office of Technology Licensing
		  	2150 Shattuck Avenue, Suite 510
		  	Berkeley, CA 94704-1347
		  	Attn.: Director (UC Case No.: [***])
		
	To LICENSEE:	  	Avalanche Biotechnologies, Inc
		  	[***]
		  	Attn.: [***]

 Either party may change its address upon written notice to the other party. 

 

	24.	LATE PAYMENTS 

  

	 	24.1	If monies owed to REGENTS under this Agreement are not received by REGENTS when due, LICENSEE will pay to REGENTS interest charges at at [***], however, in no case will the rate exceed [***] percent ([***]%) per annum.
Such interest will be calculated from the date payment was due until actually received by REGENTS. Such accrual of interest will be in addition to, and not in lieu of, enforcement of any other rights of REGENTS related to such late payment.
Acceptance of any late payment will not constitute a waiver under Article 25 (Waiver) of this Agreement. 

  

	25.	WAIVER 

  

	 	25.1	The failure of either party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement will not constitute a waiver of that right or excuse a similar subsequent failure to
perform any such term or condition by the other party. None of the terms and conditions of this Agreement can be waived except by the written consent of the party waiving compliance. 

  
 23 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	26.	CONFIDENTIALITY 

  

	 	26.1	Each party will hold the other party’s proprietary business and technical information, patent prosecution material and other proprietary information, including the negotiated terms of this Agreement, in confidence
and against disclosure to third parties with at least the same degree of care as it exercises to protect its own data and license agreements of a similar nature. This obligation will expire [***] years after the termination or expiration of this
Agreement. 

  

	 	26.2	Nothing contained herein will in any way restrict or impair the right of LICENSEE or REGENTS to use, disclose, or otherwise deal with any information or data which: 

 

	 	(a)	at the time of disclosure to a receiving party is generally available to the public or thereafter becomes generally available to the public by publication or otherwise through no act of the receiving party;

  

	 	(b)	the receiving party can show by written record was in its possession prior to the time of disclosure to it hereunder and was not acquired directly or indirectly from the disclosing party; or 

 

	 	(c)	is independently made available to the receiving party without restrictions as a matter of right by a third party. 

In addition, nothing contained herein will in any way restrict or impair the right of LICENSEE or REGENTS to make any disclosure required under
the California Public Records Act or pursuant to other requirements of law. 
  

	 	26.3	REGENTS will be free to release to the inventors and senior administrators employed by REGENTS the terms and conditions of this Agreement upon their request. If such release is made, REGENTS will inform such employees
of the confidentiality obligations set forth above and will request that they do not disclose such terms and conditions to others. Should a third party inquire whether a license to REGENTS’ PATENT RIGHTS is available, REGENTS may disclose the
existence of this Agreement and the extent of the grant in Articles 3 and 4 to such third party, but will not disclose the name of LICENSEE unless LICENSEE has already made such disclosure publicly, except where REGENTS is required to release
information under either the California Public Records Act or other applicable law, provided REGENTS gives prior written notice to LICENSEE of such disclosure. 

  
 24 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	 	26.4	LICENSEE and REGENTS agree to destroy or return to the disclosing party proprietary information received from the other in its possession within [***] following the effective date of termination of this Agreement.
However, each party may retain one copy of proprietary information of the other solely for archival purposes in non-working files for the sole purpose of verifying the ownership of the proprietary information, provided such proprietary information
will be subject to the confidentiality provisions set forth in Article 26.1. LICENSEE and REGENTS agree to provide each other, within [***] following termination of this Agreement, with a written notice that proprietary information has been returned
or destroyed. 

  

	27.	FORCE MAJEURE 

  

	 	27.1	Except for LICENSEE’s obligation to make any payments to REGENTS hereunder, the parties to this Agreement shall be excused from any performance required hereunder if such performance is rendered impossible or
unfeasible due to any catastrophes or other major events beyond their reasonable control, including, without limitation, war, riot, and insurrection; laws, proclamations, edicts, ordinances, or regulations; strikes, lockouts, or other serious labor
disputes; and floods, fires, explosions, or other natural disasters. When such events have abated, the parties’ respective obligations hereunder will resume. 

 

	28.	SEVERABILITY 

  

	 	28.1	The provisions of this Agreement are severable, and in the event that any provision of this Agreement will be determined to be invalid or unenforceable under any controlling body of law, such invalidity or
enforceability will not in any way affect the validity or enforceability of the remaining provisions hereof. 

  

	29.	APPLICABLE LAW; VENUE; ATTORNEYS’ FEES 

  

	 	29.1	THIS AGREEMENT WILL BE CONSTRUED, INTERPRETED, AND APPLIED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, excluding any choice of law rules that would direct the application of the laws of another jurisdiction,
but the scope and validity of any patent or patent application under REGENTS’ PATENT RIGHTS will be determined by the applicable law of the country of such patent or patent application. Any legal action brought by the parties relating to this
Agreement will be conducted in San Francisco, California. The prevailing party in any legal action under this Agreement will be entitled to recover its reasonable attorneys’ fees in addition to its costs and necessary disbursements.

  
 25 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

	30.	SCOPE OF AGREEMENT 

  

	 	30.1	This Agreement incorporates the entire agreement between the parties with respect to the subject matter hereof, and this Agreement may be altered or modified only by written amendment duly executed by the parties
hereto. 

  
 26 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their duly
authorized officers or representatives. 
  

									
	 THE REGENTS OF THE

UNIVERSITY OF CALIFORNIA
	 	AVALANCHE BIOTECHNOLOGIES, INC.
				
	 By
	 	/s/ Irvin Mettler	 	By	 	 /s/ Mitchell H. Finer

		 	Irvin Mettler, Ph.D.	 	
		 	Associate Director	 	Printed Name	 	 Mitchell H. Finer

		 	Office of Technology Licensing	 	Title Chief Operating Officer
			
	 Date
	 	June 1, 2010	 	Date May 28, 2010

  
 27 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]